-
Marinus Pharmaceuticals NASDAQ:MRNS Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety potential. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 3 trial in refractory status epilepticus, Phase 2 trial in tuberous sclerosis complex and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.
Location: | Website: www.marinuspharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
50.22M
Cash
64.68M
Avg Qtr Burn
-30.12M
Short % of Float
15.15%
Insider Ownership
10.94%
Institutional Own.
83.04%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ganaxolone (ZTALMY) Details Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder | Approved Quarterly sales | |
Ganaxolone Details Tuberous sclerosis complex | Phase 3 Update | |
Ganaxolone Details Epilepsy, Refractory Status Epilepticus | Phase 3 Update | |
Ganaxolone (Second generation formulation) Details Lennox-Gastaut syndrome | Phase 2 Initiation | |
Ganaxolone Details Established Status Epilepticus | Failed Discontinued |